NLRP3 Regulates IL-4 Expression in TOX+ CD4+ T Cells of Cutaneous T Cell Lymphoma to Potentially Promote Disease Progression
Open Access
- 16 June 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
Abstract
In cutaneous T cell lymphoma (CTCL), a dominant Th2 profile associated with disease progression has been proposed. Moreover, although the production and regulation of IL-4 expression during the early stages of the disease may have important implications in later stages, these processes are poorly understood. Here, we demonstrate the presence of TOX+ CD4+ T cells that produce IL-4+ in early-stage skin lesions of CTCL patients and reveal a complex mechanism by which the NLRP3 receptor promotes a Th2 response by controlling IL-4 production. Unassembled NLRP3 is able to translocate to the nucleus of malignant CD4+ T cells, where it binds to the human il-4 promoter. Accordingly, IL-4 expression is decreased by knocking down and increased by promoting the nuclear localization of NLRP3. We describe a positive feedback loop in which IL-4 inhibits NLRP3 inflammasome assembly, thereby further increasing its production. IL-4 induced a potentially malignant phenotype measured based on TOX expression and proliferation. This mechanism of IL-4 regulation mediated by NLRP3 is amplified in late-stage CTCL associated with disease progression. These results indicate that NLRP3 might be a key regulator of IL-4 expression in TOX+ CD4+ T cells of CTCL patients and that this mechanism might have important implications in the progression of the disease.This publication has 35 references indexed in Scilit:
- Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysisBritish Journal of Cancer, 2014
- Overexpression of hypoxia‐inducible factor 1 alpha impacts FoxP3 levels in mycosis fungoides—Cutaneous T‐cell lymphoma: Clinical implicationsInternational Journal of Cancer, 2013
- TH2 Cytokines from Malignant Cells Suppress TH1 Responses and Enforce a Global TH2 Bias in Leukemic Cutaneous T-cell LymphomaClinical Cancer Research, 2013
- STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphomaCell Cycle, 2013
- Molecular Markers of Early-Stage Mycosis FungoidesJournal of Investigative Dermatology, 2012
- Dermal infiltrates of cutaneous T-cell lymphomas with epidermotropism but not other cutaneous lymphomas are abundant with langerin+ dendritic cellsJournal of the European Academy of Dermatology and Venereology, 2010
- How are TH1 and TH2 effector cells made?Current Opinion in Immunology, 2009
- TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)Blood, 2007
- The Pathogenesis of Mycosis FungoidesThe New England Journal of Medicine, 2004
- Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factorThe Journal of Experimental Medicine, 1981